跳至主要内容
临床试验/KCT0006837
KCT0006837尚未招募未知

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

ational Cancer Center0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19?(Year) 至 o Limit(—)
性别
All

入选标准

  • 1 Disease Related Criteria
  • - Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC).
  • - Patient must have an MRI of the brain performed within 28 days prior to registration documenting no evidence of brain metastases or leptomeningeal
  • disease. Patient also must not have a history of brain metastases or leptomeningeal disease.
  • 2 Prior/Concurrent Therapy Criteria
  • - Immunotherapy concurrent with and/or adjuvant to first-line therapy is allowed at the discretion of the treating physician. Patients with LS-SCLC must
  • have completed platinum-based chemotherapy and either definitive thoracic radiotherapy (including SBRT for early-stage T1-2 N0 M0 disease who do
  • not undergo surgery) or definitive surgical resection; thoracic radiation in addition to definitive surgical resection is allowed at the discretion of the
  • treating physician but is not required. Patients with ES-SCLC must have completed the platinum-based chemotherapy component of their treatment
  • - All adverse events from prior treatment must have resolved to = Grade 2 (CTCAE Version 5.0) prior to randomization.
  • - Patient must have had a response to first-line therapy and no evidence of progression in opinion of the treating investigator. Systemic imaging (CT or PET/CT including the chest and abdomen) must be performed within 42 days prior to randomization.
  • - No more than 16 weeks may have elapsed between Day 1 of the last cycle of chemotherapy and randomization.
  • - Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy. Patients who have undergone prior stereotactic radiosurgery
  • for benign tumors or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis. Please
  • contact Dr. Chad Rusthoven at chad.rusthoven@cuanschutz.edu for inquiries.
  • 3 Clinical/Laboratory Criteria
  • -Patient must be = 18 years of age. (Korea = 19)
  • -Patient must have Zubrod Performance Status of 0-2 (see Section 10.9).
  • -Patient must not have a contraindication to MR imaging, such as implanted metal devices or foreign bodies.
  • - Patient must not have a contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
  • - Patient must not have other metastatic malignancies requiring current active treatment.
  • - Patient must not have any severe active comorbidities, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within 3 months prior to randomization
  • Transmural myocardial infarction within 3 months prior to randomization
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization
  • Acute severe exacerbation of chronic obstructive pulmonary disease or other acute respiratory illness precluding study therapy at the time of
  • randomization
  • Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease
  • HIV positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly
  • active antiretroviral therapy (HAART) and have a CD4 count = 200 cells/microliter within 16 weeks prior to randomization. Note also that HIV testing
  • is not required for eligibility for this protocol.
  • - Patient must not be pregnant because of fetal risks from radiation

排除标准

  • Included in inclusion criteria

研究者

发起方
ational Cancer Center

相似试验